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Background: Cervical cancer claims the lives of 275,000 women each year; most of these deaths occur in low-or
middle-income countries. In Kenya, cervical cancer is the leading cause of cancer-related mortality among women
of reproductive age. Kenya’s Ministry of Public Health and Sanitation has developed a comprehensive strategy to
prevent cervical cancer, which includes plans for vaccinating preteen girls against human papillomavirus (HPV) by
2015. To identify HPV vaccine communication and mobilization needs, this research sought to understand HPV
vaccine-related perceptions and concerns of male and female caregivers and community leaders in four rural
communities of western Kenya.
Methods: We conducted five focus groups with caregivers (n = 56) and 12 key-informant interviews with opinion
leaders to explore cervical cancer-related knowledge, attitudes and beliefs, as well as acceptability of HPV
vaccination for 9–12 year-old girls. Four researchers independently reviewed the data and developed codes
based on questions in interview guides and topics that emerged organically, before comparing and reconciling
results through a group consensus process.
Results: Cervical cancer was not commonly recognized, though it was understood generally in terms of its symptoms.
By association with cancer and genital/reproductive organs, cervical cancer was feared and stigmatized. Overall
acceptability of a vaccine that prevents cervical cancer was high, so long as it was endorsed by trusted agencies and
communities were sensitized first. Some concerns emerged related to vaccine safety (e.g., impact on fertility), program
intent, and health equity.
Conclusion: For successful vaccine introduction in Kenya, there is a need for communication and mobilization efforts
to raise cervical cancer awareness; prompt demand for vaccination; address health equity concerns and stigma; and
minimize potential resistance. Visible endorsement by government leaders and community influencers can provide
reassurance of the vaccine’s safety, efficacy and benefits for girls and communities. Involvement of community
leadership, parents and champions may also be critical for combatting stigma and making cervical cancer relevant to
Kenyan communities. These findings underscore the need for adequate planning and resources for information,
education and communication prior to vaccine introduction. Specific recommendations for communication and
social-marketing strategies are made.
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Each year, nearly 530,000 women develop cervical cancer
and almost 270,000 die from it worldwide [1]. Most of these
deaths occur in low- or middle-income countries (LMIC)
with limited or no cervical-cancer screening programs.
Kenya has one of the highest rates of cervical cancer in the
world [2]. Among Kenyan women of reproductive age, cer-
vical cancer is the most common cancer diagnosed and the
leading cause of cancer-related mortality [3]. Kenya has de-
veloped a comprehensive strategy to address this disease,
which includes rollout of vaccination against the human
papillomavirus (HPV) among girls [4].
HPV vaccines are safe and effective, and have achieved
90% efficacy in preventing cervical pre-cancers in young
women naïve to the targeted HPV types [5-8]. The
World Health Organization (WHO) recommends routine
HPV vaccination for girls aged 9–13 years when feasible
and sustainable, and where prevention of cervical cancer
or other HPV-related diseases constitute a public health
priority [9,10]. The GAVI Alliance is supporting an HPV
vaccine demonstration project in Kenya in 2013–2014
[11]. HPV vaccination presents unique challenges for
implementation, given its three-dose series, protection
against an infection that causes disease decades later,
and target population of adolescent girls only [12,13].
It is critical to understand communities’ vaccine-related
perceptions and concerns to identify information, educa-
tion and communication (IEC) needs for successful vac-
cine introduction [14-16]. Whereas formative research
and pilot projects have been conducted in LMIC such as
India, Peru, Vietnam, Uganda and other African countries
[16]; there has been limited research in Kenya on HPV
vaccine acceptability for young girls. Two available studies
suggest that Kenyan mothers would be willing to accept
a vaccine for their daughters to prevent cervical can-
cer, despite limited awareness of cervical cancer and
other potential barriers, including concerns about side ef-
fects (infertility), cost, multiple doses and spouse disapproval
[17,18]. However, to date there has been no published re-
search from Kenya on HPV vaccine acceptability among
spouses (i.e., fathers of young girls) or community leaders,
who may play critical roles in vaccine uptake [19,20].
This study sought to explore sociocultural factors as-
sociated with HPV vaccine acceptability among opinion
leaders and both male and female caregivers in a western
province of Kenya. This article reports on caregivers’
and leaders’ cervical cancer and vaccination knowledge,
attitudes and beliefs; and perceived acceptability of and
barriers and facilitators to HPV vaccination, with impli-
cations for future HPV vaccine introduction.
Methods
Qualitative research was conducted with caregivers and
opinion leaders in three rural locations and one peri-urbanlocation of Siaya County, Kenya, in July-August 2012. Siaya
is among the poorest of Kenya’s 47 counties [21]. It ranks
among the highest in child and maternal morbidity and
mortality in all of Kenya [22], and has a higher HIV/AIDS
prevalence rate compared to national averages [23,24]. The
study sites were located within a Health and Demographic
Surveillance System (HDSS) established by the Kenya
Medical Research Institute (KEMRI) and the U.S. Centers
for Disease Control and Prevention (CDC), which covers
a population of approximately 220,000. The study design
was approved by the KEMRI Ethics Review Committee
(Scientific Steering Committee #2167). This study adheres
to the Qualitative Research Review (RATS) guidelines for
reporting qualitative studies.
We conducted a total of five focus groups with care-
givers (four groups of women and one of men) and 12 key-
informant interviews with opinion leaders. Focus groups
were used to prompt and observe in-depth, dynamic dis-
cussions among caregivers about cancer and vaccination;
whereas interviews were intended to draw on the experi-
ences and perceptions of community leaders. Open-ended,
semi-structured discussion/interview guides were used to
explore participants’ knowledge, attitudes and beliefs re-
garding cervical cancer and HPV vaccine acceptability for
9–12 year-old girlsa. Interview guides were developed by
CDC staff and revised with in-country project staff at
KEMRI/CDC for cultural appropriateness and relevance.
Caregiver focus groups were segmented by gender and led
by a trained moderator, who was matched to participant
gender to allow for open discussions of sensitive repro-
ductive and sexual health issues. A greater number of focus
groups were conducted with female caregivers since re-
search suggests that mothers have primary responsibility
for vaccine decision making; however, fathers may also be
important household decision makers, whose perspectives
impact a mother’s vaccination decisions [20]. The five
focus groups allowed for a diversity of perspectives and to
reach data saturation.
Caregivers were recruited by community mobilizers
in three locations and through an ongoing parent-
focused program (directed at improving HIV-prevention
knowledge and communication skills) in the fourth
location. Sampling was purposive, intended to gather
a diversity of opinions among hard-to-reach caregivers
in high-morbidity areas. Prospective participants attended
a screening and consent session, during which they were
informed about study objectives and participant rights
and confidentiality; screened for eligibility; and con-
sented if eligible. Participants were eligible if they re-
ported being the caregiver of a girl aged 9–12 years
and residing within the HDSS. Focus-group discus-
sions were conducted in Dholuo (local language) and
held at the chief ’s camp of each location; they lasted two
hours each.
Friedman et al. BMC Public Health 2014, 14:855 Page 3 of 10
http://www.biomedcentral.com/1471-2458/14/855Opinion leaders were recruited during a District Stake-
holder Meeting and through referrals. Consent to par-
ticipate was obtained prior to interviews, which were
held at the location of each participant’s choosing. Each
Interview lasted approximately one-and-a-half hours and
was conducted in respondents’ language of choice.
Data analysis
Focus group discussions were digitally recorded, tran-
scribed and translated into English. A minimum of two
team members reviewed transcripts to ensure the accur-
acy and completeness of translations against focus group
notes and clarify any cultural references or direct trans-
lations. Transcripts were then analyzed using NVivo8
qualitative software. For interviews, detailed notes were
taken and then reviewed by interviewer and note-taker
to identify gaps and ensure accuracy and completeness.
Notes were then coded and analyzed using concept
matrices.
Grounded Theory method was used to analyze the
data [25]. Four researchers independently reviewed the
data and developed codes (themes) based on questions
in interview guides and topics that emerged organically
[26]. Using the codebook definitions, two researchers
independently coded segments from the focus group
transcripts and compared results. Through a group
consensus process [25,26], reliability was calculated by
hand; coding discrepancies were discussed and recon-
ciled, and revisions to the codebook were made. This
process was repeated until a satisfactory level of agree-
ment was reached. Reliability was checked at least one
other time to ensure that coding remained consistent. The
same consensus process was used for the interview notes.
None of the researchers occupied dual roles.
Results
Characteristics of the sample
A total of 56 caregivers and 12 opinion leaders partici-
pated. Caregivers had an average of five children; most
(79%) were married and one-quarter had not completed
primary education (Table 1). In contrast, most (67%)
opinion leaders had completed college or university; they
represented leaders in health (n = 4), community rela-
tions (n = 3), and one each in immunizations, politics,
religious organizations, education and media.
Awareness, knowledge, beliefs and perceptions
Cancer
Awareness of cancer was high among caregivers and opin-
ion leaders. It was commonly described as an infection,
wound, or abnormal growth affecting specific body parts.
Participants regarded it as a serious, painful, and fatal dis-
ease that is incurable or difficult and expensive to treat.
They acknowledged a sense of fear and shame associatedwith cancer, noting those affected “cannot freely socialize
with others” and may be treated as outcasts and viewed
as cursed.
Cervical cancer and HPV
The majority of caregivers and opinion leaders had not
previously heard of cervical cancer, though most recog-
nized it, once explained by its symptoms, as a cancer of
the female reproductive organs. Caregivers described it
using local terms to refer to a wound or sexually trans-
mitted infection (STI) of the stomach or womb; some
confused it with other conditions in the genital or ab-
dominal area, such as fibroids. By association with can-
cer, it was viewed as a serious and deadly disease for
which treatment is expensive, inaccessible, unaffordable
and ineffective. It was presumed to affect a woman’s
ability to bear children.
Aside from health experts, participants were not aware
of HPV or its link to cervical cancer, though most as-
sumed cervical cancer was associated with sexual behav-
ior or poor hygiene. A majority of focus groups believed
a woman could become infected during sexual activity
from her male partner’s penile impurities. Other pre-
sumed causes included having sex while menstruating,
multiple partners, an STI that doesn’t heal, or a partner
who is unfaithful; not bathing properly; and sexual initi-
ation at a young age, particularly with an older man.
Once informed about HPV, participants had many ques-
tions (Table 2), reflecting confusion about its causes
and natural history, modes of transmission, symptoms,
health effects, treatment and prevention in men and
women.
Participants reported diseases of the genital area were
associated with shame and stigma. While caregivers did
not believe cervical cancer to be common locally, several
acknowledged it was not something people talk about,
so it may silently impact their communities. They noted
a cervical cancer diagnosis could cause blame or abuse
between a woman and her husband. A majority of opin-
ion leaders also noted women with cervical cancer may
be unsupported or socially isolated from their communi-
ties, particularly if they cannot bear children.
“It’s viewed like HIV and AIDS. If you have it, people
don’t want to talk to you. You’re seen as an outcast in
the community.” – Opinion Leader
Acceptability of a cervical cancer vaccine
With the exception of health and media experts (n = 3),
no participants across focus groups or interviews had
heard of the HPV vaccine. Once informed of a safe and
effective vaccine against cervical cancer available for
young girls, caregivers and opinion leaders were will-
ing and eager to accept it. The majority of caregivers
Table 1 Focus group participant and key informant demographics
Focus groups participants (N = 56) Key informants (N = 12)
n (%) Mean (SD) Range n (%) Mean (SD) Range
Age (years) – 38.3 (8.7) 18-62 – 44.6 (14.0) 24-67
Gender
Female 44 (78.6%) – – 7 (58.3%) – –
Male 12 (21.4%) – – 5 (41.7%) – –
Marital status
Married 44 (78.6%) – – 10 (83.3%) – –
Widowed 12 (21.4%) – – 1 (8.3%) – –
Single – 1 (8.3%)
Education
No schooling 1 (1.8%) – – – –
Primary incomplete 14 (25.0%) – – 1 (8.3%) – –
Primary complete 16 (28.6%) – – 1 (8.3%) – –
Secondary incomplete 11 (19.6%) – – 2 (16.7%) – –
Secondary complete 13 (23.2%) – – – – –
Tertiary/college 1 (1.8%) – – 5 (41.7%) – –
University – – – 3 (25%) – –
Location
East Alego 12 (21.4%) – – 1 (8.3%) – –
South Alego 12 (21.4%) – – 4 (33.3%) – –
S.E. Alego 11 (19.6%) – – 3 (25%) – –
Siaya Township 21 (37.5%) – – 4 (33.3%)
Number of children in home
Number of daughters – 2.7 (1.3) 0-5 – 2.5 (1.8) 0-5
Number of sons – 2.3 (1.7) 0-7 – 2.4 (1.6) 1-6
Age range of children within home (years) – – 3-34 – – 3-26
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dations) about vaccine safety. They were familiar with
other childhood vaccines and believed them to be ef-
fective disease-prevention tools based on experiences
seeing other diseases eradicated and vaccinated chil-
dren growing up healthy.
“There could be a change in the future of women… just
like the case of cholera, nowadays it is unheard of.” –
Opinion Leader
The prevention of cancer for the future health of girls
and communities was a primary motivator for vaccin-
ation across participant groups. The vaccine was seen as
a way to protect children from a disease associated with
pain, suffering and financial cost. Many cited a desire for
their children to have a better future. Similarly, opinion
leaders supported the vaccine as a life-saving and cost-
reducing measure that could improve their communities’social well-being. Preservation of a girl’s future fertility
and averting cervical-cancer treatment costs were also
motivators.
“Cancerous infection is a disease that is greatly feared
and if parents are well informed about it then they
would not have a reason to oppose it.” –Caregiver
A vaccine for girls only was seen as acceptable by care-
givers, if communities are properly educated (e.g., that
cervical cancer affects only women). Half of opinion
leaders thought it would be ideal to vaccinate boys too,
both to promote health equity and to maximize impact;
some noted the possibility of stigmatizing or embarras-
sing girls by singling them out. Nonetheless, three-
quarters of them agreed that vaccinating girls only was a
reasonable public-health solution, given the high cost of
vaccination, the country’s limited resources and the need
to focus efforts where need is greatest.
Table 2 Common questions from caregivers
HPV HPV vaccine
Causes and natural history Vaccine implementation
• Where do people get HPV from? • How and where will the vaccine be administered to girls?
• Is HPV hereditary? • Will it be given to all girls in Kenya?
• Does HPV infect bodily fluids or blood? • What other countries have implemented the vaccine?
• Does HPV only travel to the cervix (or does it affect other organs)?
• What does HPV do to men? Vaccine benefits & alternatives
• How will it help us?
HPV epidemiology • Is there another way of preventing cervical cancer?
• Does HPV mostly affect women?
• If HPV cannot be seen, how do we know that most people
have it at some point?
Vaccine safety & side effects
• Has the vaccine been tested?
• Is it being tested on our children?
Modes of transmission • What are the side effects of this vaccine?
• Is it acquired through sexual intercourse? • Does the vaccine affect future fertility?
• Are there other (non-sexual) ways you can get it?
• Do men and women transmit HPV to each other? Vaccine effectiveness
• Will girls be prevented from cervical cancer after they are vaccinated?
Symptoms and effects on the body • What is the duration of protection?
• What are the signs and symptoms of HPV? • Will the vaccine work if it’s given to a girl who already has cervical cancer?
• How long does it take for them to appear? • Will it still help if a girl misses a dose?
• How does one know if they are infected?
• Could HPV turn into HIV? Age & gender concerns
• Does HPV cause herpes? • Why is it administered to girls aged 9–12 years, when cancer affects women (older)?
• Can HPV prevent a woman from getting pregnant, or
having a healthy pregnancy?
• If most everyone has HPV then why are only children vaccinated and
not adults? Why not boys?
• Does it cause other cancers or problems (e.g., prostate
cancer in men)?
• Can the vaccine be given to girls aged 9–12 if they haven’t started
monthly periods?
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cancer that affects the reproductive system of women,
it would be ok to vaccinate girls only.” –Caregiver
Caregivers did not comment on the proposed age of
vaccination but they acknowledged preadolescence as an
age during which girls may have sexual risk. Several opin-
ion leaders noted the proposed age seemed appropriate,
though a minority (n = 3) were concerned the range was
too narrow. They argued that some girls would need to be
vaccinated earlier to receive protection prior to sexual de-
but, and older girls who had not yet had sex should still
be able to benefit from vaccination. Whereas two opinion
leaders suggested parents might be concerned about their
vaccinated daughters becoming “careless” with sex, this
concern was only voiced by one male caregiver.
Questions and possible barriers to HPV vaccination
Caregivers were prompted for questions or concerns they
would want addressed before vaccinating their daughters.
Common questions (Table 2) related to vaccine safetyand side effects (e.g., infertility), followed by vaccine ef-
fectiveness, age- and gender-related questions, the nature
of the vaccine program, and vaccine delivery. Caregivers
also expressed a desire to know more about cervical can-
cer, its consequences and impact on the community, and
alternative prevention strategies.
Several themes emerged from discussions about po-
tential fears and cultural/community barriers to vaccin-
ation, as described below.
1. Lack of community awareness and education
Widespread ignorance about cervical cancer and the
vaccine emerged as primary barriers to vaccination.
Participants noted that the absence of education
could result in low demand for vaccination, and
potentially damaging rumors or misconceptions
could fill the gaps in knowledge.
2. Cultural Beliefs
Participants across groups identified cultural beliefs
as potential challenges to vaccination, particularly
among the elderly, traditional herbalists and some
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in preventive health services; and specific religious
groups that reject modern medicine. Two focus
groups discussed beliefs that vaccines cause more
harm than good, including prolonged crying and fever
in the short term. According to two opinion leaders,
some people believe vaccinations are small injections
of disease causing disease or death. However, these
cultural attitudes were thought to be held by a
minority and amenable to change with education.
3. Adverse events
Participants noted adverse events and side effects,
including pain or physical reactions, could
discourage vaccine series completion. Opinion
leaders feared rumors could spread from real or
perceived adverse events, and that negative
experiences, such as long wait times or rude staff,
could also inhibit vaccine uptake.
4. Access Challenges
Challenges reaching girls with three doses of a
vaccine, including transportation, demands on time
and competing priorities were noted, particularly for
clinics, since long travel distances may be required.
Girls may also be reluctant to visit clinics, with
aversions from past experience of injection pain and
suboptimal care. Whereas school settings might
conveniently reach a majority of girls, this would
miss out-of-school girls and girls who are absent
from school on the day of vaccination.
5. Stigma
Opinion leaders noted that sexual health may be
taboo and parents may struggle to talk to their
children about prevention of cervical cancer. They
also expressed concern that girls could be presumed
sick (e.g. HIV-positive) and stigmatized if seen
making multiple visits to a health center. Similarly,
caregivers felt that school or community settings
could present privacy challenges, introducing the
potential for embarrassment or ridicule of girls by
their peers due to presumed associations with puberty,
participation in a research study, or illness/HIV.
6. Fears, Rumors and Distrust
A lack of information, coupled with distrust of the
medical community held by a minority of
community members, could lead to concerns or
rumors about the intent of the vaccination effort. A
few opinion leaders noted that communities might
fear that their daughters are being used for research
or distrust the intent of “whites” or foreign agencies
supporting the program. Concerns about infertility
(as a side effect) or suspicions about a covert
sterilization effort were mentioned by half of opinion
leaders and in two focus groups, though sterilization
concerns were more predominant among malecaregivers. Targeting young girls for vaccination
rather than older women, who are affected by the
disease, could fuel these suspicions.
“There are people in the community who are fond of
spreading rumors. They may inform the parents that
their children are only being used for research
purposes and the vaccine would be of no help to their
children.” – Caregiver
Facilitators to vaccination
Community mobilization and sensitization were seen as
critical for raising cervical cancer awareness; prompting
demand for vaccination; and helping to overcome stigma.
Participants discussed the need to educate mothers and
fathers (as family-level decision makers), as well as girls.
They suggested promoting community dialogue and edu-
cation through organizations and events (e.g., Chief ’s
meetings, schools, churches, funerals, workshops, aware-
ness rallies/walks, concerts); champions (e.g., cervical can-
cer survivors, affected families, health care providers); and
mass media, advertising and print information. Opinion
leaders suggested approaching communities in an “ethical”
manner, educating them based on existing beliefs and
addressing concerns in culturally sensitive ways through
leaders (e.g., chiefs, community mobilizers, health workers,
teachers and school administrators). Most believed po-
tential “resisters” would be amenable to vaccination, if
approached with culturally appropriate education from
traditional leaders (e.g., registered herbalists, religious
leaders).
“Cervical cancer is like a new thing…We need to face
realities. Find an approach to reduce stigma so we can
address the disease. Let us not hide from it because we
are in denial.” –Opinion Leader
Other facilitators included convenient, safe and access-
ible community settings for vaccination that assure pa-
tient privacy; competent, trusted and friendly staff;
and endorsement by government, hospitals and med-
ical institutions. Finally, experts emphasized the import-
ance of leveraging lessons learned from past programs,
including having a government policy in place to sup-
port vaccination and integrating vaccination into other
health services (e.g., school health or community outreach
programs).
“Once you have a policy in place, they [parents] follow
the policy.” – Opinion Leader
Discussion
This research sought to explore factors associated with
HPV vaccine acceptability among caregivers and opinion
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preparation for vaccine introduction. Although cancer
was a widely known and feared disease, cervical cancer
was not commonly recognized. It was understood gen-
erally in terms of its symptoms, as a disease that is
linked to sexual risk factors [20,27] and infertility. It was
feared and seen as shameful; something that is not openly
discussed. Overall acceptability of a vaccine that prevents
cervical cancer was high, if endorsed by trusted govern-
ment agencies and if communities are properly sensitized.
Our findings are similar to those in other LMIC where
there is limited knowledge of cervical cancer, a general
awareness and high perceived severity of cancer, and
high acceptability and perceived value of vaccines for dis-
ease prevention [18,20,27,28]. They underscore the need
for mass-media and community efforts to raise cervical
cancer awareness [17,18] and address stigma for successful
vaccine introduction in Kenya. Visible endorsement
by government leaders [19,29] and support from com-
munity influencers (e.g., chiefs, community health workers,
teachers/school administrators) [30], as well as both par-
ents, will be critical for uptake [17,19]. Involvement of
leadership and community champions may also be critical
for combatting stigma and making cervical cancer relevant
to Kenyan communities [31,32].Table 3 HPV vaccine communication objectives
Raise cervical cancer awareness &
understanding
• Cervical cancer is a serio
• It often strikes women in
• It is one of the most com
• Each year in Kenya, abou
Create demand for HPV vaccine • A vaccine can prevent g
the arm. Three doses are
Address safety concerns • It is best if the vaccine b
age ensures that they ar
Address concerns about sterilization • It is best if the vaccine b
age ensures that they ar
Build on positive vaccine perceptions and
emphasize perceived benefits
•The vaccine protects the
o By vaccinating young g
for their own children a
o Prevention is better tha
Create realistic expectations of vaccine to
help minimize rumors or false expectations
• The most common side
mild fever, headache, or
• The vaccine does not pr
Address health equity concerns • The vaccine is intended
men. But everyone can
o Parents can take their d
o Women can get screen
problems can be found
o Men can support their
o Everyone can start talkiA well-planned and funded strategic communication/
mobilization plan can help reach and maintain vaccine
coverage [33]. In Kenya, an effective strategy should not
only address cervical cancer awareness, stigma and the
need for vaccination, but issues of vaccine safety, efficacy
and delivery, including potential concerns regarding its
effect on fertility and intent of the program [20,27,28,34]
(Table 3). Such concerns may be prompted by the vac-
cine’s focus on young girls, its perceived ‘newness’, and
its origination in high-income countries [25,26]. Rumors
or confusion could be particularly important to address
in vaccine demonstration projects, which could be mis-
understood as research trials. Trusted leaders can clar-
ify misconceptions and provide assurances of vaccine
safety, program goals and vaccination benefits [20,27,35].
Trained mobilizers can help contain resistance from indi-
viduals or groups, which can negatively impact commu-
nity acceptance [12].
Gain-framed messaging (i.e., promoting the benefits of
vaccination, rather emphasizing the consequences of not
getting vaccinated), which builds on positive perceptions
of vaccines, may be most effective in promoting HPV
vaccination [20,27,36] and help minimize stigma [37].
Implementers should consider marketing the vaccine as
a “cervical cancer vaccine” [20,27,28,34] that promotesus disease that affects a woman’s cervix.
their 30’s and 40’s. But it starts to develop many years earlier.
mon cancers in women worldwide and a main cause of cancer death.
t 2,500 women get cervical cancer and 2,000 women die from it.
irls from getting cervical cancer later in life. It is given as an injection in
needed for full protection.
e given to girls around the ages of 9–13 years. Vaccinating girls at this
e protected long before cervical cancer begins to develop.
e given to girls around the ages of 9–13 years. Vaccinating girls at this
e protected long before cervical cancer begins to develop.
reproductive health of girls/women.
irls, we can protect their health and their future – so they can be around
nd families.
n treatment or cure.
effects are pain, redness or swelling in the arm. Some girls may get a
nausea.
otect against HIV or STDs such as chlamydia or gonorrhea.
primarily for prevention of cervical cancer, a disease that does not affect
help prevent cervical cancer.
aughters to get vaccinated.
ed for cervical cancer (Pap test or visual inspection) so that early
and treated – even before cancer develops.
wives, sisters and mothers in getting screened for cervical cancer.
ng openly about cervical cancer and educating others about prevention.
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that people are motivated to prevent and reproductive
health is highly valued in Kenya. In contrast, HPV gener-
ated much confusion among caregivers, distracting from
the issue of cervical cancer.
The proposed age of vaccination did not prompt care-
giver concerns about sexual disinhibition, as it has else-
where [27,35]. However, some opinion leaders expressed
health-equity concerns, preferring that all females
(young and old), as well as boys, have access to vaccin-
ation [28]. Additionally, the singling out of girls was
regarded as potentially stigmatizing or embarrassing for
them. These challenges can be addressed (at least in part)
with communication and social marketing strategies, in-
cluding: (a) raising awareness that cervical cancer only af-
fects women; (b) marketing vaccine delivery as a package
of cervical-cancer prevention tools, which also includes
screening for women; and/or (c) integrating HPV vac-
cination into other health outreach or school-health pro-
grams so that girls are vaccinated as part of broader
public-health interventions rather than singled out. Inte-
gration into school health efforts has been effectively
achieved in other African countries [19,29,38], though cost
and delivery challenges may impede the long-term sus-
tainability of such efforts and there is a need for further
delivery strategies to reach girls not in school, who may be
in greatest need [39]. A combination of school-based and
health facility-based delivery methods may therefore offer
the greatest promise for effectively reaching girls with
HPV vaccination in LMICs such as Kenya [40]. These pro-
grams could be supported by text-based reminders or
other digital media tools to promote series comple-
tion [41]. To realize this promise, however, critical in-
frastructure, service quality and delivery challenges
will need to be addressed— from staff training to cold
chain and reporting systems [42]. GAVI demonstration
projects are currently underway to identify the best, most
affordable and sustainable HPV vaccine delivery strategies
in LMICs with weak health systems or immunization pro-
grammes [43].
Conclusion
This study is the first to assess HPV vaccine acceptability
among both male and female caregivers and opinion
leaders in Kenya. It underscores the need for adequate
planning and resources for IEC prior to vaccine introduc-
tion to raise awareness of cervical cancer, prompt demand
for vaccination, and minimize stigma and potential resist-
ance. These results are based on a small sample of care-
givers and opinion leaders (from limited fields of expertise
and geographic areas) recruited through KEMRI/CDC
and may not be generalizable. It is possible that partici-
pants were influenced by social desirability (given that the
research was conducted by a health agency), or that theydiffered in their opinions on vaccination and public-health
institutions from caregivers and opinion leaders who did
not participate in the study. Details on those who chose
not to participate (and why) were not collected, which is a
study limitation. However, results are intended to be dir-
ectional in nature, informing future efforts. Future evalua-
tions should include caregivers and opinion leaders from
different regions and cultural/ethnic affiliations, including
multi-level school and policy leaders and experts in cancer
prevention, immunization, STI prevention and adolescent
health, as well as young girls themselves. Such research
should be supported by health-systems and policy re-
search to assess capacities, structures, processes and policy
environments for vaccine implementation.
Endnote
aParents of 9–12 year-old girls were selected for this
research because this (9–12 years) was the tentatively
targeted age range for HPV vaccination efforts in Kenya
at the time this research protocol was developed.
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